ENGN vs EXOZ

enGene Therapeutics Inc. vs eXoZymes Inc. — Valuation Comparison 2026

ENGN

Biological Products, (No Diagnostic Substances)
enGene Therapeutics Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.85
Last close
Models
8/13
Active
VS

EXOZ

Biological Products, (No Diagnostic Substances)
eXoZymes Inc.
Quality
4.5
out of 10
Value Trap
Price
$9.85
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ENGN Fair ValueENGN Upside EXOZ Fair ValueEXOZ Upside
Bayesian DCF Intrinsic $0.54 -70.9% $2.50 -74.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.93 +4.2%
Dynamic NAV Asset-Based $3.11 +68.1% $0.29 -97.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENGN vs EXOZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENGN vs EXOZ — Which Stock Is More Undervalued?

EXOZ scores higher with a 4.5/10 quality rating vs ENGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing enGene Therapeutics Inc. (ENGN) and eXoZymes Inc. (EXOZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENGN currently trades at $1.85 with a QOC of 4.1/10, while EXOZ trades at $9.85 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).